Kymera Therapeutics, INC

Kymera Therapeutics announced the appointment of Dr. Terence Rooney as Chief Medical Officer, succeeding Dr. Jared Gollob who is retiring.

Kymera Therapeutics has completed enrollment in its Phase 2b BROADEN2 trial for KT-621 six months ahead of schedule.

Kymera Therapeutics shareholders re-elected four Class III directors and ratified the appointment of Ernst & Young LLP.

Kymera Therapeutics announced the resignation of its Chief Operating Officer, Jeremy Chadwick, who will transition to an advisory role until November 2026.

Kymera Therapeutics reported Q1 2026 financial results, highlighting strong collaboration revenue and providing updates on its STAT6 and IRF5 degrader programs, with significant cash reserves extending runway into 2029.

Kymera Therapeutics, Inc. has amended its bylaws to designate federal district courts as the exclusive forum for Securities Act and Exchange Act claims.

Kymera Therapeutics reported increased collaboration revenue and R&D expenses in Q1 2026, with cash reserves projected to last into 2029.

Kymera Therapeutics reports a significant increase in net losses for Q3 and the first nine months of 2025, alongside strategic program adjustments and a new collaboration.

Kymera Therapeutics reports increased losses and a strategic pipeline shift, securing significant funding to extend its cash runway into late 2028.

Kymera Therapeutics announces its Q1 2025 financial results, showcasing increased collaboration revenue and advancements in its clinical-stage targeted protein degradation programs.

Kymera Therapeutics reports a net loss of $62.5 million for the third quarter of 2024, while highlighting progress in its immunology pipeline and strategic decisions regarding oncology programs.

Kymera Therapeutics reports a net loss of $42.1 million for Q2 2024, while progressing its clinical programs and maintaining a strong cash position.

Kymera Therapeutics reports significant progress in its clinical pipeline, including positive Phase 1b results for KT-621 in Atopic Dermatitis, new collaborations, and substantial capital raises, despite continued operating losses.

Kymera Therapeutics' 2024 10-K filing highlights clinical advancements in immunology programs and a strong financial position to support operations into mid-2027.

Kymera Therapeutics, a biopharmaceutical company, released its 2023 annual report, highlighting its progress in targeted protein degradation therapies and ongoing clinical trials.

Terence Rooney, Chief Medical Officer of Kymera Therapeutics, Inc., reported multiple transactions in common stock on July 27, 2026.

Kymera Therapeutics CEO Nello Mainolfi executed trades involving company stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

Kymera Therapeutics' Chief Financial Officer, Bruce N. Jacobs, reported transactions involving the sale of common stock and the acquisition of stock options on June 30, 2026, executed under a Rule 10b5-1 trading plan.

Noah Goodman, Chief Business Officer at Kymera Therapeutics, Inc., reported transactions involving common stock, including purchases made under a Rule 10b5-1 trading plan.

Nello Mainolfi, CEO of Kymera Therapeutics, executed a series of stock transactions on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth, a Director at Kymera Therapeutics, has filed an amended Form 4 detailing adjustments to his beneficial ownership of common stock, primarily related to sales executed under a Rule 10b5-1 trading plan.

Kymera Therapeutics announces its 2025 Annual Meeting of Shareholders to be held virtually on June 25, 2025, with voting open until June 24, 2025.

Kymera Therapeutics announces its 2025 Annual Meeting of Shareholders to be held virtually on June 25, 2025, featuring proposals for director elections, executive compensation approval, and auditor ratification.

Kymera Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Kymera Therapeutics announces its 2024 Annual Meeting of Shareholders to be held virtually on June 18, 2024, featuring proposals including director elections, executive compensation, and an amendment to the stock option plan.

BVF Partners and affiliated entities sold 1,630,658 shares of Kymera Therapeutics at $106.50 per share on June 26, 2026.

BVF Partners and affiliated entities have updated their beneficial ownership in Kymera Therapeutics, Inc. to 8.5% following an increase in the issuer's outstanding shares.

Baker Bros. Advisors LP and its affiliates increased their beneficial ownership in Kymera Therapeutics, Inc. to 10.9% by participating in a recent public offering.

Baker Bros. Advisors and its affiliated funds have increased their beneficial ownership in Kymera Therapeutics, Inc. to 9.5% of outstanding common stock after participating in a recent public offering of shares and prefunded warrants.

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 4.8% of Kymera Therapeutics, Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a significant beneficial ownership stake of 14.3% in Kymera Therapeutics Inc. as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Kymera Therapeutics Inc. following an internal realignment, with subsidiaries now reporting separately.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership in Kymera Therapeutics, Inc. common stock.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 11.2% in Kymera Therapeutics Inc. common stock as of December 31, 2025.

T. Rowe Price Associates, Inc. has reported an increased beneficial ownership of 7.1% in Kymera Therapeutics Inc. common stock.